Scolyer provides a clinical consultation service for the diagnosis of difficult pigmented lesions and receives more than 2,000 cases for opinion from Australasia and beyond annually. He integrates his clinical practice with co-leading a translational melanoma research laboratory.[7]
In February 2019, he was ranked the world's 10th leading publisher on the topic of melanoma and the world's leading publisher in melanoma pathology.[8] Scolyer has co-authored more than 700 publications and book-chapters on the subject,[4][7] and was an editor of the fourth edition of the WHO classification of tumours of the central nervous system.[9]
Cancer diagnosis and treatment
This section needs expansion. You can help by adding to it. (January 2024)
In June 2023, Scolyer was diagnosed with a stage 4 glioblastoma IDH wild-type brain tumour.[10][1] With treatment for glioblastoma mostly unchanged for the last 20 years, Georgina Long worked to develop a world-first treatment for Scolyer's brain tumour based on breakthroughs in melanoma research. Scolyer underwent experimental combination immunotherapy before and after surgical excision of the tumour, delaying his surgery to do so. Scolyer was also administered a cancer vaccine personalised to the tumour genetic markers, in order to help the immunotherapy detect the cancer cells. His treatment was documented in the journal Nature Medicine,[11] paving the way for future clinical trials. While medical oncologists have applied these techniques successfully to melanoma, this treatment is non-standard for brain cancer due to concerns about toxicity, whether drugs will reach the brain, and speed of tumour development.[12]
In February 2024, eight months after surgery, Scolyer's cancer had not returned. This was an encouraging result with potentially broader implications due to the pioneering approach taken, with the normal prognosis for this glioblastoma being six to nine months, though oncologists warned that it was too early to judge the effectiveness of the treatment, compared to standard protocols.[13] On 10 March 2025, Scolyer announced the cancer had returned, and he was given a prognosis of three months.[14][15]
Awards and recognition
Scolyer received the New South Wales Premier's Award for Outstanding Cancer Research in 2009, 2012, 2013, 2014, 2016, 2017, 2018 and 2020.[16]
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.
